JP2017517266A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517266A5 JP2017517266A5 JP2016572447A JP2016572447A JP2017517266A5 JP 2017517266 A5 JP2017517266 A5 JP 2017517266A5 JP 2016572447 A JP2016572447 A JP 2016572447A JP 2016572447 A JP2016572447 A JP 2016572447A JP 2017517266 A5 JP2017517266 A5 JP 2017517266A5
- Authority
- JP
- Japan
- Prior art keywords
- triphosphate
- rna molecule
- sequence
- bioreactor
- ntp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 239000001226 triphosphate Substances 0.000 claims 14
- 235000011178 triphosphate Nutrition 0.000 claims 14
- 239000002342 ribonucleoside Substances 0.000 claims 10
- 239000011541 reaction mixture Substances 0.000 claims 8
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 claims 8
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 7
- -1 ribonucleoside triphosphates Chemical class 0.000 claims 7
- 230000002194 synthesizing Effects 0.000 claims 7
- 230000035897 transcription Effects 0.000 claims 7
- 238000000338 in vitro Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 238000005457 optimization Methods 0.000 claims 6
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 4
- 238000003786 synthesis reaction Methods 0.000 claims 4
- PGAVKCOVUIYSFO-XVFCMESISA-N Uridine triphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 claims 3
- 230000000875 corresponding Effects 0.000 claims 3
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 3
- 238000001914 filtration Methods 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 239000002777 nucleoside Substances 0.000 claims 3
- PCDQPRRSZKQHHS-XVFCMESISA-N ({[({[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-XVFCMESISA-N 0.000 claims 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 229920000110 poly(aryl ether sulfone) Polymers 0.000 claims 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims 2
- 229920003288 polysulfone Polymers 0.000 claims 2
- 229950010342 uridine triphosphate Drugs 0.000 claims 2
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 108020004417 Untranslated RNA Proteins 0.000 claims 1
- CYZZKTRFOOKUMT-LMVFSUKVSA-N [(2R,3S,4S)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound O[C@H]1CO[C@H](COP(O)(O)=O)[C@H]1O CYZZKTRFOOKUMT-LMVFSUKVSA-N 0.000 claims 1
- HNPYBPXXPMVWIY-LMVFSUKVSA-N [(2R,3S,4S)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound O[C@H]1CO[C@H](COP(O)(=O)OP(O)(O)=O)[C@H]1O HNPYBPXXPMVWIY-LMVFSUKVSA-N 0.000 claims 1
- GKVHYBAWZAYQDO-XVFCMESISA-N [[(2R,3S,4R,5R)-3,4-dihydroxy-5-(2-oxo-4-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=S)C=C1 GKVHYBAWZAYQDO-XVFCMESISA-N 0.000 claims 1
- YIJVOACVHQZMKI-JXOAFFINSA-N [[(2R,3S,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 YIJVOACVHQZMKI-JXOAFFINSA-N 0.000 claims 1
- VEWJOCYCKIZKKV-BLOUUBGSSA-N [[(2R,5S)-5-(2,4-dioxo-1H-pyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound OC1C(O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1C1=CNC(=O)NC1=O VEWJOCYCKIZKKV-BLOUUBGSSA-N 0.000 claims 1
- KHYOUGAATNYCAZ-XVFCMESISA-J [[[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate Chemical compound O1[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=S)NC(=O)C=C1 KHYOUGAATNYCAZ-XVFCMESISA-J 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 230000000977 initiatory Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 1
- 229920001894 non-coding RNA Polymers 0.000 claims 1
- 230000003287 optical Effects 0.000 claims 1
- 229920002239 polyacrylonitrile Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 239000004627 regenerated cellulose Substances 0.000 claims 1
- 239000011342 resin composition Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Claims (17)
- 所与の配列のRNA分子を合成する方法であって、
a)前記RNA分子における4種のヌクレオチドG、A、C、及びUの各割合(1)を求める工程と、
b)配列最適化反応ミックス中でインビトロ転写によって前記RNA分子を合成する工程であって、前記配列最適化反応ミックスが、4種のリボヌクレオシド三リン酸(NTP
)GTP、ATP、CTP、及びUTPを含み、前記配列最適化反応ミックス中の前記4種のリボヌクレオシド三リン酸の各割合(2)が、前記RNA分子、バッファ、DNAテンプレート、及びRNAポリメラーゼ中の各ヌクレオチドの割合(1)に対応する工程と
を含むことを特徴とする方法。 - 前記工程b)が、
b1)前記4種のリボヌクレオシド三リン酸(NTP)GTP、ATP、CTP、及びUTPを含む配列最適化リボヌクレオシド三リン酸(NTP)ミックスを調製する工程であって、前記配列最適化リボヌクレオシド三リン酸(NTP)ミックス中の前記4種のリボヌクレオシド三リン酸の各割合(2)が、前記RNA分子中の各ヌクレオチドの割合(
1)に対応する工程と、
b2)工程(b1)の前記NTPミックス、バッファ、DNAテンプレート、及びRNAポリメラーゼを含む配列最適化反応ミックス中でインビトロ転写によって前記RNA分子を合成する工程と
を含む請求項1に記載の方法。 - 前記インビトロ転写の開始前に、前記RNA分子の第1のヌクレオチドに対応する出発ヌクレオチドを前記配列最適化反応ミックスに添加する請求項1から2のいずれかに記載の方法。
- 前記出発ヌクレオチドが、ヌクレオシド一リン酸、ヌクレオシド二リン酸、ヌクレオシド三リン酸、又はジヌクレオシド三リン酸、若しくはキャップアナログである請求項3に記載の方法。
- 前記出発ヌクレオチドが、前記RNA分子の第1の位置にみられる前記RNA分子におけるヌクレオチドの割合に比べて過剰に添加される請求項3から4のいずれかに記載の方法。
- 前記RNA分子の前記第1のヌクレオチドに対応しないヌクレオチドについて、前記割合(1)と前記割合(2)との差が最大10%である請求項1から5のいずれかに記載の方法。
- 少なくとも1つのリボヌクレオシド三リン酸の一部又は全てが、修飾ヌクレオシド三リン酸によって置換されており、前記修飾ヌクレオシド三リン酸が、好ましくは、シュードウリジン−5’−トリホスフェート、1−メチルシュードウリジン−5’−トリホスフェート、2−チオウリジン−5’−トリホスフェート、4−チオウリジン−5’−トリホスフェート、及び5−メチルシチジン−5’−トリホスフェートからなる群から選択される請求項1から6のいずれかに記載の方法。
- 前記インビトロ転写の過程で、請求項2のb1)に記載の前記配列最適化リボヌクレオシド三リン酸(NTP)ミックスを前記配列最適化反応ミックスに補充する請求項1から7のいずれかに記載の方法。
- 前記RNA分子が、非コードRNA分子及びコードRNA分子からなる群から選択され、好ましくはmRNAである請求項1から8のいずれかに記載の方法。
- 前記RNA分子が、100ヌクレオチドよりも長い、及び/又は所与の配列のRNA分子の合成が、大規模合成で実施される、及び/又は前記NTPの対イオンが、トリス(ヒドロキシメチル)−アミノメタン(Tris)である請求項1から9のいずれかに記載の方法。
- インビトロ転写による前記RNA分子の合成後に、未取り込みNTPを分離及び定量する請求項1から10のいずれかに記載の方法。
- インビトロ転写による前記RNA分子の合成が、バイオリアクタ(1)内で実施され、前記バイオリアクタ(1)が、好ましくは、固体担体に固定化されているDNAテンプレートを含む請求項1から11のいずれかに記載の方法。
- 前記バイオリアクタ(1)が、前記配列最適化反応ミックスからヌクレオチドを分離するための濾過膜(21)を含み、前記濾過膜(21)が、好ましくは、再生セルロース、変性セルロース、ポリスルホン(PSU)、ポリアクリロニトリル(PAN)、ポリメチルメタクリレート(PMMA)、ポリビニルアルコール(PVA)、及びポリアリールエーテルスルホン(PAES)の群から選択される請求項12に記載の方法。
- 前記濾過膜(21)が、約10kDa〜約50kDaの範囲の分子量カットオフを有する請求項13に記載の方法。
- 前記バイオリアクタ(1)が、反応中のヌクレオチド濃度をリアルタイムに測定するためのセンサユニット(41)を含み、前記センサユニット(41)が、好ましくは、光分析によって前記ヌクレオチド濃度を測定する請求項12から14のいずれかに記載の方法。
- 前記バイオリアクタが、請求項2のb1)に記載の前記配列最適化リボヌクレオシド三リン酸(NTP)ミックスの添加を制御する制御モジュール(4)を含む、及び/又は前記バイオリアクタ(1)が、請求項2のb1)に記載の前記配列最適化リボヌクレオシド三リン酸(NTP)ミックスを添加するアクチュエータ(43)を含む、及び/又は前記バイオリアクタ(1)が、前記RNA分子を捕捉し、転写反応ミックスの他の成分から前記RNA分子を分離するための樹脂を含む、及び/又は前記バイオリアクタ(1)が、半バッチモード又は連続モードで動作する請求項12から15のいずれかに記載の方法。
- 前記バイオリアクタ(1)が、少なくとも1つのイオン選択性電極を含み、前記少なくとも1つのイオン選択性電極が、好ましくは、前記バイオリアクタ(1)の少なくとも1つの区画に含まれる液体中の1種以上のイオンの濃度を測定するために用いられ、前記イオンが、好ましくは、H + 、Na + 、K + 、Mg 2+ 、Ca 2+ 、Cl − 、及びPO 4 3− からなる群から選択される請求項12から16のいずれかに記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP2014/001577 | 2014-06-10 | ||
EP2014001577 | 2014-06-10 | ||
PCT/EP2015/001164 WO2015188933A1 (en) | 2014-06-10 | 2015-06-10 | Methods and means for enhancing rna production |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017517266A JP2017517266A (ja) | 2017-06-29 |
JP2017517266A5 true JP2017517266A5 (ja) | 2018-05-31 |
JP6748579B2 JP6748579B2 (ja) | 2020-09-02 |
Family
ID=51033109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016572447A Active JP6748579B2 (ja) | 2014-06-10 | 2015-06-10 | Rna生成を強化する方法及び手段 |
Country Status (15)
Country | Link |
---|---|
US (2) | US10837039B2 (ja) |
EP (2) | EP3155129B1 (ja) |
JP (1) | JP6748579B2 (ja) |
KR (1) | KR102459599B1 (ja) |
CN (1) | CN106661621B (ja) |
AU (1) | AU2015273933B2 (ja) |
BR (1) | BR112016026980B1 (ja) |
CA (1) | CA2945629C (ja) |
ES (1) | ES2727776T3 (ja) |
MX (1) | MX2016016170A (ja) |
PL (1) | PL3155129T3 (ja) |
PT (1) | PT3155129T (ja) |
RU (1) | RU2738753C2 (ja) |
SG (1) | SG11201608605QA (ja) |
WO (1) | WO2015188933A1 (ja) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
RS59037B1 (sr) | 2011-06-08 | 2019-08-30 | Translate Bio Inc | Kompozicije lipidnih nanočestica i postupci za isporuku irnk |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
CA2903880A1 (en) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Methods and compositions for delivering mrna coded antibodies |
ES2967701T3 (es) | 2013-03-15 | 2024-05-03 | Translate Bio Inc | Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas |
SG11201510746WA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Respiratory syncytial virus (rsv) vaccine |
CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
EP3540060A1 (en) | 2013-12-30 | 2019-09-18 | CureVac AG | Methods for rna analysis |
WO2015101416A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Methods for rna analysis |
CA2936286A1 (en) | 2014-04-01 | 2015-10-08 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
JP6748579B2 (ja) | 2014-06-10 | 2020-09-02 | キュアバック リアル エステート ゲゼルシャフト ミット ベシュレンクテル ハフツング | Rna生成を強化する方法及び手段 |
EP4241784A3 (en) | 2014-12-12 | 2023-11-15 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
WO2016165825A1 (en) | 2015-04-13 | 2016-10-20 | Curevac Ag | Method for producing rna compositions |
EP3283125B1 (en) | 2015-04-17 | 2021-12-29 | CureVac Real Estate GmbH | Lyophilization of rna |
EP3289101B1 (en) | 2015-04-30 | 2021-06-23 | CureVac AG | Immobilized poly(n)polymerase |
EP3294885B1 (en) | 2015-05-08 | 2020-07-01 | CureVac Real Estate GmbH | Method for producing rna |
US11559570B2 (en) | 2015-05-15 | 2023-01-24 | CureVac SE | Prime-boost regimens involving administration of at least one mRNA construct |
US10517827B2 (en) | 2015-05-20 | 2019-12-31 | Curevac Ag | Dry powder composition comprising long-chain RNA |
CN107530448A (zh) | 2015-05-20 | 2018-01-02 | 库瑞瓦格股份公司 | 包含长链rna的干粉组合物 |
EP3744843A1 (en) | 2015-05-29 | 2020-12-02 | CureVac Real Estate GmbH | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
WO2016193226A1 (en) | 2015-05-29 | 2016-12-08 | Curevac Ag | Method for adding cap structures to rna using immobilized enzymes |
US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
US11225682B2 (en) | 2015-10-12 | 2022-01-18 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
EP3373965A1 (en) | 2015-11-09 | 2018-09-19 | CureVac AG | Rotavirus vaccines |
AU2016375021B2 (en) | 2015-12-22 | 2022-02-03 | CureVac SE | Method for producing RNA molecule compositions |
US11248223B2 (en) | 2015-12-23 | 2022-02-15 | Curevac Ag | Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
SG11201806340YA (en) | 2016-02-17 | 2018-09-27 | Curevac Ag | Zika virus vaccine |
EP3423595A1 (en) | 2016-03-03 | 2019-01-09 | CureVac AG | Rna analysis by total hydrolysis |
KR102369898B1 (ko) | 2016-04-08 | 2022-03-03 | 트랜슬레이트 바이오 인코포레이티드 | 다량체 코딩 핵산 및 그 용도 |
US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
EP3452493A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Nucleic acid molecules and uses thereof |
WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
KR20190029576A (ko) | 2016-06-09 | 2019-03-20 | 큐어백 아게 | 핵산 카고용 하이브리드 담체 |
EP3469074B1 (en) | 2016-06-13 | 2020-12-09 | Translate Bio, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
CN109937253B (zh) * | 2016-09-14 | 2023-06-30 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
WO2018096179A1 (en) | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
CN110177544A (zh) | 2016-11-29 | 2019-08-27 | 普尔泰克健康有限公司 | 用于递送治疗剂的外泌体 |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
CN110582304A (zh) | 2016-12-08 | 2019-12-17 | 库尔维科公司 | 用于治疗或预防肝脏疾病的rna |
EP3558354A1 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Lassa virus vaccine |
EP3558355A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Henipavirus vaccine |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
US11920148B2 (en) | 2017-02-22 | 2024-03-05 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
MA47607A (fr) * | 2017-02-27 | 2020-01-01 | Translate Bio Inc | Synthèse à grande échelle d'arn messager |
CA3050614A1 (en) | 2017-03-17 | 2018-09-20 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
EP3601576A1 (en) | 2017-03-24 | 2020-02-05 | CureVac AG | Nucleic acids encoding crispr-associated proteins and uses thereof |
WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
WO2018195404A1 (en) * | 2017-04-21 | 2018-10-25 | The Board Of The Trustees Of The Leland Stanford Junior University | Ultra-sensitive and universal species detection pipeline for next generation sequencing data |
WO2018211038A1 (en) | 2017-05-17 | 2018-11-22 | Curevac Ag | Method for determining at least one quality parameter of an rna sample |
CN111328287A (zh) | 2017-07-04 | 2020-06-23 | 库瑞瓦格股份公司 | 新型核酸分子 |
US11001868B2 (en) * | 2017-08-11 | 2021-05-11 | Global Life Sciences Solutions Operations UK Ltd | Cell-free protein expression using double-stranded concatameric DNA |
EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
WO2019092153A1 (en) | 2017-11-08 | 2019-05-16 | Curevac Ag | Rna sequence adaptation |
EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
AU2018392716A1 (en) | 2017-12-20 | 2020-06-18 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
WO2019122371A1 (en) | 2017-12-21 | 2019-06-27 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
EP3773702A2 (en) | 2018-04-05 | 2021-02-17 | CureVac AG | Novel yellow fever nucleic acid molecules for vaccination |
CN112292395A (zh) | 2018-04-17 | 2021-01-29 | 库瑞瓦格股份公司 | 用于疫苗接种的新型rsv rna分子和组合物 |
EP3813874A1 (en) | 2018-06-27 | 2021-05-05 | CureVac AG | Novel lassa virus rna molecules and compositions for vaccination |
WO2020002598A1 (en) | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
AU2019410737A1 (en) | 2018-12-21 | 2021-06-10 | CureVac SE | RNA for malaria vaccines |
MX2021011031A (es) * | 2019-03-11 | 2021-12-10 | Modernatx Inc | Proceso de transcripción in vitro en lotes alimentados. |
US11578348B2 (en) * | 2019-04-24 | 2023-02-14 | The University Of Massachusetts | Enzymatic methods to generate high yields of sequence specific rna with extreme precision |
EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
CA3144902A1 (en) * | 2019-08-14 | 2022-01-19 | Andreas Thess | Rna combinations and compositions with decreased immunostimulatory properties |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
BR112022014627A2 (pt) | 2020-02-04 | 2022-09-27 | Curevac Ag | Vacina contra coronavírus |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
WO2021168052A1 (en) * | 2020-02-18 | 2021-08-26 | Translate Bio, Inc. | Improved processes for in vitro transcription of messenger rna |
GB2597436A (en) * | 2020-05-12 | 2022-02-02 | Univ Cranfield | A method and apparatus for RNA synthesis |
JP2023528586A (ja) * | 2020-05-12 | 2023-07-05 | クランフィールド ユニヴァーシティー | Rnaを用いた治療薬の合成方法及び合成モジュール式装置 |
EP3993828A1 (en) | 2020-05-29 | 2022-05-11 | CureVac AG | Nucleic acid based combination vaccines |
US20230272052A1 (en) | 2020-07-31 | 2023-08-31 | CureVac SE | Nucleic acid encoded antibody mixtures |
CA3170743A1 (en) | 2020-08-31 | 2022-03-03 | Susanne RAUCH | Multivalent nucleic acid based coronavirus vaccines |
EP4208286A1 (en) | 2020-09-01 | 2023-07-12 | CureVac RNA Printer GmbH | Manufacturing device for a pharmaceutical product |
CN116547077A (zh) | 2020-11-27 | 2023-08-04 | 库瑞瓦格Rna打印机有限公司 | 用于通过毛细管聚合酶链式反应制备dna产物的设备 |
AU2021395736A1 (en) * | 2020-12-09 | 2023-07-27 | BioNTech SE | Rna manufacturing |
CA3205569A1 (en) | 2020-12-22 | 2022-06-30 | CureVac SE | Rna vaccine against sars-cov-2 variants |
WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
CN114717230A (zh) * | 2021-01-05 | 2022-07-08 | 麦塞拿治疗(香港)有限公司 | 成纤维细胞生长因子mRNA的无细胞和无载体体外RNA转录方法和核酸分子 |
CN114717229A (zh) * | 2021-01-05 | 2022-07-08 | 麦塞拿治疗(香港)有限公司 | 治疗性mRNA的无细胞和无载体体外RNA转录方法和核酸分子 |
WO2022162027A2 (en) | 2021-01-27 | 2022-08-04 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
US20240181038A1 (en) | 2021-03-26 | 2024-06-06 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
AU2022305101A1 (en) * | 2021-06-30 | 2024-02-01 | Etherna Immunotherapies Nv | Method for rna manufacturing |
TWI814499B (zh) * | 2021-07-22 | 2023-09-01 | 中央研究院 | 用以連續製備及分析rna的裝置以及利用該裝置來合成rna的方法 |
WO2023007019A1 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
AU2021461416A1 (en) * | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
US20230279376A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
TW202403046A (zh) | 2022-03-21 | 2024-01-16 | 瑞士商Crispr治療公司 | 用於治療脂蛋白相關的疾病之方法及組成物 |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
DE202023106198U1 (de) | 2022-10-28 | 2024-03-21 | CureVac SE | Impfstoff auf Nukleinsäurebasis |
WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256555A (en) | 1991-12-20 | 1993-10-26 | Ambion, Inc. | Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions |
US5434079A (en) | 1993-02-12 | 1995-07-18 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and process for continuous in vitro synthesis of proteins |
WO1995008626A1 (en) * | 1993-09-20 | 1995-03-30 | The Regents Of The University Of Colorado | Strategy for the production of rna from immobilized templates |
EP1800697B1 (de) | 2001-06-05 | 2010-04-14 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
DE10240868A1 (de) * | 2002-09-04 | 2004-03-18 | Artus Gesellschaft für molekularbiologische Diagnostik und Entwicklung mbH | Verbesserte Verfahren zur Synthese von Nukleinsäuren |
EP1649056A1 (en) | 2003-07-02 | 2006-04-26 | Caliper Life Sciences, Inc. | Methods for amplifying and detecting nucleic acids in microfluidic devices under continuous and non-continuous flow conditions. |
DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
US20050287539A1 (en) | 2004-06-29 | 2005-12-29 | Emmanuel Labourier | Methods and compositions for preparing capped RNA |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
LT2578685T (lt) | 2005-08-23 | 2019-06-10 | The Trustees Of The University Of Pennsylvania | Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai |
CA2659301A1 (en) | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
EA017740B1 (ru) | 2007-06-19 | 2013-02-28 | Борд Оф Сьюпервайзорз Оф Луизиана Стэйт Юниверсити Энд Эгрикалчурал Энд Мекэникал Колледж | Синтез и применение антиинвертированных фосфоротиоатных аналогов кэп-структуры матричной phk |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
EP3346005A1 (en) | 2008-01-31 | 2018-07-11 | CureVac AG | Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant |
PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
US20120208242A1 (en) | 2009-10-21 | 2012-08-16 | Riboxx Gmbh | Method and RNA Reactor for Exponential Amplification of RNA |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
US9388373B2 (en) | 2011-03-08 | 2016-07-12 | University Of Maryland Baltimore County | Microscale bioprocessing system and method for protein manufacturing |
RS59037B1 (sr) | 2011-06-08 | 2019-08-30 | Translate Bio Inc | Kompozicije lipidnih nanočestica i postupci za isporuku irnk |
US9862926B2 (en) * | 2011-06-27 | 2018-01-09 | Cellscript, Llc. | Inhibition of innate immune response |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
US8969545B2 (en) | 2011-10-18 | 2015-03-03 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
AU2013242404B2 (en) | 2012-03-27 | 2018-08-30 | CureVac SE | Artificial nucleic acid molecules for improved protein or peptide expression |
BR112014023898A2 (pt) | 2012-03-27 | 2017-07-11 | Curevac Gmbh | moléculas de ácido nucleico artificiais compreendendo 5''utr top |
KR102186497B1 (ko) | 2012-03-27 | 2020-12-04 | 큐어백 아게 | 인공 핵산 분자 |
AU2013243951A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
EP3498267A1 (en) | 2012-05-25 | 2019-06-19 | CureVac AG | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
SG11201510746WA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Respiratory syncytial virus (rsv) vaccine |
WO2015024664A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Composition and vaccine for treating prostate cancer |
CA2915730A1 (en) | 2013-08-21 | 2015-02-26 | Karl-Josef Kallen | A combination rsv/influenza a vaccine |
CN105517569A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 狂犬病疫苗 |
SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
HUE046469T2 (hu) | 2013-08-21 | 2020-03-30 | Curevac Ag | Készítmény és vakcina tüdõrák kezelésére |
CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
BR112016014462A2 (pt) | 2013-12-30 | 2017-10-24 | Curevac Ag | moléculas de ácido nucleico artificiais |
WO2015101416A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Methods for rna analysis |
ES2754239T3 (es) | 2014-03-12 | 2020-04-16 | Curevac Ag | Combinación de vacunación y agonistas de OX40 |
CA2936286A1 (en) | 2014-04-01 | 2015-10-08 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
JP6748579B2 (ja) | 2014-06-10 | 2020-09-02 | キュアバック リアル エステート ゲゼルシャフト ミット ベシュレンクテル ハフツング | Rna生成を強化する方法及び手段 |
EP4241784A3 (en) | 2014-12-12 | 2023-11-15 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
WO2016097065A1 (en) | 2014-12-16 | 2016-06-23 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
EP3240558A1 (en) | 2014-12-30 | 2017-11-08 | CureVac AG | Artificial nucleic acid molecules |
MX2017013321A (es) | 2015-04-22 | 2018-07-06 | Curevac Ag | Composicion que contiene arn para tratamiento de enfermedades tumorales. |
EP3294885B1 (en) | 2015-05-08 | 2020-07-01 | CureVac Real Estate GmbH | Method for producing rna |
-
2015
- 2015-06-10 JP JP2016572447A patent/JP6748579B2/ja active Active
- 2015-06-10 US US15/317,579 patent/US10837039B2/en active Active
- 2015-06-10 ES ES15738263T patent/ES2727776T3/es active Active
- 2015-06-10 KR KR1020167035028A patent/KR102459599B1/ko active IP Right Grant
- 2015-06-10 SG SG11201608605QA patent/SG11201608605QA/en unknown
- 2015-06-10 CA CA2945629A patent/CA2945629C/en active Active
- 2015-06-10 RU RU2017100044A patent/RU2738753C2/ru active
- 2015-06-10 WO PCT/EP2015/001164 patent/WO2015188933A1/en active Application Filing
- 2015-06-10 AU AU2015273933A patent/AU2015273933B2/en active Active
- 2015-06-10 PL PL15738263T patent/PL3155129T3/pl unknown
- 2015-06-10 PT PT15738263T patent/PT3155129T/pt unknown
- 2015-06-10 EP EP15738263.1A patent/EP3155129B1/en active Active
- 2015-06-10 CN CN201580031536.2A patent/CN106661621B/zh active Active
- 2015-06-10 EP EP18001012.6A patent/EP3521456B1/en not_active Revoked
- 2015-06-10 BR BR112016026980-2A patent/BR112016026980B1/pt active IP Right Grant
- 2015-06-10 MX MX2016016170A patent/MX2016016170A/es unknown
-
2020
- 2020-10-15 US US17/071,279 patent/US20210040526A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017517266A5 (ja) | ||
RU2017100044A (ru) | Способы и средства повышения продуктивности рнк | |
JP2016530294A5 (ja) | ||
JP2019533476A5 (ja) | ||
DK3039158T3 (en) | MASSIVE PARALLEL SINGLE CELL CELL ANALYSIS | |
ES2827307T3 (es) | Métodos y composiciones para la síntesis de ADNc y la elaboración del perfil del transcriptoma de células individuales utilizando una reacción de cambio de plantilla | |
RU2016107198A (ru) | Аналоги нуклеотидов | |
EA202191796A2 (ru) | Способ сайт-специфического ферментативного мечения нуклеиновых кислот in vitro введением не встречающихся в природе нуклеотидов | |
WO2020120442A3 (en) | Direct oligonucleotide synthesis on cells and biomolecules | |
Kore et al. | An improved protection-free one-pot chemical synthesis of 2′-deoxynucleoside-5′-triphosphates | |
WO2009102878A3 (en) | Method for archiving and clonal expansion | |
ATE518948T1 (de) | Verbesserte polymerasen | |
JP2016535983A5 (ja) | ||
Toti et al. | Nucleosides with transposed base or 4′-hydroxymethyl moieties and their corresponding oligonucleotides | |
WO2017058810A3 (en) | Polymerase compositions and kits, and methods of using and making the same | |
Zhang et al. | Synthesis of Threose Nucleic Acid (TNA) Triphosphates and Oligonucleotides by Polymerase‐Mediated Primer Extension | |
US20220195424A1 (en) | Chemical Capping for Template Switching | |
BR112021021491A2 (pt) | Método de amplificação de mrnas e para a preparação de bibliotecas de mrna de comprimento total | |
Kaur et al. | Production of long linear DNA substrates with site-specific chemical lesions for single-molecule replisome studies | |
Li et al. | Conformation-dependent DNA attraction | |
Kore et al. | Gram‐scale chemical synthesis of 2′‐deoxynucleoside‐5′‐O‐triphosphates | |
JPWO2019199807A5 (ja) | ||
Chemama et al. | Flexible Nucleic Acids (FNAs) as Informational Molecules: Enzymatic Polymerization of fNTPs on DNA Templates and Nonenzymatic Oligomerization of RNA on FNA Templates | |
BR112017008508A2 (pt) | método para purificar oses sem ajustar o ph | |
Wei et al. | Towards Co-evolution of Membrane Transport and Metabolism |